Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 11,519 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 21.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,893 shares of the medical research company’s stock after selling 11,519 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Edwards Lifesciences were worth $2,952,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Brighton Jones LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $266,000. Bank Pictet & Cie Europe AG increased its stake in shares of Edwards Lifesciences by 16.7% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company’s stock worth $757,000 after buying an additional 1,463 shares during the period. Private Advisor Group LLC raised its holdings in Edwards Lifesciences by 79.4% during the 4th quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock valued at $1,579,000 after buying an additional 9,440 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $220,000. Finally, Lake Street Advisors Group LLC boosted its position in Edwards Lifesciences by 17.8% during the 4th quarter. Lake Street Advisors Group LLC now owns 3,661 shares of the medical research company’s stock valued at $271,000 after buying an additional 552 shares during the period. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EW shares. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, May 16th. Dbs Bank raised Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Truist Financial dropped their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Piper Sandler boosted their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, May 13th. Finally, Citigroup restated a “buy” rating and set a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average price target of $80.20.

Edwards Lifesciences Stock Up 0.3%

Shares of NYSE:EW opened at $77.19 on Friday. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $75.49 and a two-hundred day simple moving average of $73.12. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $95.25. The stock has a market capitalization of $45.28 billion, a price-to-earnings ratio of 11.03, a PEG ratio of 3.88 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the previous year, the firm earned $0.66 EPS. Edwards Lifesciences’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the transaction, the vice president now owns 47,206 shares in the company, valued at $3,295,450.86. This represents a 16.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 5,980 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer now directly owns 58,284 shares of the company’s stock, valued at approximately $4,366,054.44. This trade represents a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,648 shares of company stock worth $2,998,866 in the last three months. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.